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INTRODUCTION
Upper limb lymphedema is one of the most debilitating 
complications to breast cancer treatment. Lymphedema is as-
sociated with decreased quality of life1 and increased risk of 
serious skin infections.2 About 30% of breast cancer patients 
with axillary lymph node involvement develop lymphedema, 
and standard management is life-long compression therapy.3,4
Several reports have dealt with lymphoscintigraphy as 
a means of quantifying lymphedema and lymphatic dys-
function. Many approaches have been made including 
simple ratios between regions of interest (ROIs),5,6 time 
to axillary lymph node presentation,7 and clearance rate 
from injection depot.8,9 However, results are conflicting, 
and there is no consensus on the optimal way of quanti-
fying lymphedema, allowing for comparison before and 
after treatment, or between different therapeutic ap-
proaches.5,6,8,9
Emerging microsurgical procedures have shown 
promise for alleviating lymphedema, but recent reviews 
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have identified that only half of published studies pres-
ent a functional evaluation of the lymphatic system. 
Lymphoscintigraphy is one of the most commonly ap-
plied techniques.10,11 However, for many studies includ-
ing functional evaluation, the presentation is either not 
clear or mostly qualitative in nature, making it difficult 
to compare results across studies. Thus, there is a need 
of standardized quantitative techniques that can reliably 
reflect the lymphatic dysfunction to allow proper evalu-
ation of emerging surgical techniques.
The aim of the present study was to apply a newly de-
scribed quantification method based on lymphoscintigra-
phy and examine its correlation to lymphedema patient 
characteristics.
MATERIALS AND METHODS
Patient Characteristics
We examined 11 female patients with unilateral arm 
lymphedema following breast cancer treatment includ-
ing patients treated with axillary lymphadenectomy. All 
patients had previously been diagnosed with lymph-
edema by physiotherapists. They had received standard 
of care treatment and were in a stable phase of lymph-
edema.
Excess arm volume was calculated based on multiple 
circumference measurements.12 We measured arm circum-
ference at wrist, middle of the forearm, elbow, and middle 
of and proximally on the upper arm. Based on these 5 
measurements, the arm was divided into 4 segments, and 
the volume of each segment was calculated using the trun-
cated cone formula given in equation (1)
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where V is the segment volume, h is the length of the 
segment, and C1 and C2 are circumferences at the ends of 
the segment. The ratio between the 2 arm volumes was 
used to define excess arm volume percentage.
Body mass index (BMI) was calculated from body 
weight and height measured at the time of circumfer-
ence measurements. Hand dominance, location of 
lymphedema (hand involvement—yes/no), previous 
erysipelas infection, duration of lymphedema, and 
number of lymph nodes removed during surgery were 
registered.
Lymphoscintigraphy Protocol
Lymphoscintigraphy was performed according to a 
procedure described in detail elsewhere.13 In short, 20 
MBq technetium-99m–labeled human serum albumin 
(Tc-99m-HSA (Vasculocis; CIS Bio International, Paris, 
France) in 0.1 mL was injected in the finger web between 
the second and third fingers bilaterally and was followed 
immediately by dynamic imaging for 30 minutes. Sequen-
tial 300-second scans were performed every 30–45 minutes 
for 5 hours using a dual head Philips Skylight gamma cam-
era equipped with low-energy, high-resolution collimators.
Visual Evaluation
As a semiquantitative visual evaluation, we used the 
scoring system described previously by Szuba et al.5 This 
system evaluates 2 parameters, dermal backflow and vi-
sualization of axillary lymph nodes giving a total score 
between 0 and 8, where 0 is normal and 8 is the highest 
severity of lymphedema. Two physicians scored the 2 pa-
rameters; disagreements were solved by consensus.
Quantitative Evaluation
The quantitative evaluation was performed as de-
scribed in detail elsewhere.13 Briefly, for estimation of 
mean transit time (MTT) of the tracer, ROIs were man-
ually drawn on each time frame (Fig. 1). Time activity 
curves from each ROI were background and decay cor-
rected. The time activity curve of the injection depot was 
described by a 2-phase clearance function.14 The activity 
input into the arm from the injection depot was calculated 
as the (minus) time derivative of the modeled injection 
time activity function. The measured arm time activity 
curve was mathematically described by a convolution of 
the input function and a retention function. The reten-
tion function reflects the sojourn time of activity entering 
the arm from the injection depot remaining in the arm 
compartment until it exited the arm compartment prox-
imally. The best fit of the convolution function and the 
measured arm activity curve were obtained using the least 
square fitting method “NonlinearModelFit” from the soft-
ware Wolfram Mathematica v10.0 (Wolfram Research Inc, 
Champaign, Ill.). MTT was calculated as the time integral 
of the retention function.
Statistical Analysis
MTT is given as mean ± SD. Statistical analysis was 
performed using STATA/IC14 (StataCorp, LP, College 
Station, Tex.). Comparison between arms was made with 
the paired samples t test, and between other groups the 
independent t test was used. Bivariate correlation was cal-
culated using Spearman’s rank correlation as associations 
were assumed to be monotonic and nonlinear. A 2-tailed P 
value < 0.05 was considered statistically significant.
Ethics
This study was part of a clinical trial (NCT02592213) 
registered with the Danish Data Protection Agency (2008-
58-0035) and approved by the Regional Ethics Committee 
(S-20150109).
RESULTS
Included patients had a median age of 52 years (range, 
34–68) and a median BMI of 31 kg/m2 (range, 22.3–
41.8). The duration of lymphedema ranged from 8 to 55 
months. Five patients had lymphedema of the dominant 
arm, and 7 had lymphedema involving the hand. The me-
dian excess arm volume was 12.4% (range, 5.8–27.0%). 
The median Szuba score was 6 (range, 3–8). See Table 1 
for characteristics of included patients.
There was a clear and highly significant difference in 
mean MTT between the 2 arms; mean MTT in lymphedema 
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arms (MTTlymph) was 60.1 ± 27.7 minutes versus 5.4 ± 2.5 min-
utes in the normal, unaffected arms (MTTnorm; mean differ-
ence, 54.7 minutes; 95% confidence interval [CI], 36.5–72.9 
minutes; P < 0.0001). This was in contrast to the result when 
looking exclusively on the removal rate from the injection 
site, where there was no significant difference between arms 
(0.127 ± 0.053%/min versus 0.132 ± 0.040%/min; P = 0.76).
Four of the included patients had previously been 
treated for erysipelas in their lymphedema arm. In these, 
MTTlymph was significantly longer, that is, mean MTTlymph 
87.0 ± 11.4 minutes versus 41.7 ± 17.0 minutes in patients 
without prior erysipelas (mean difference, 43.7 minutes; 
95% CI, 18.6–68.7 minutes; P < 0.001). In the bivariate cor-
relation analysis, this naturally lead to a strong correlation 
between MTTlymph and previous erysipelas (r = 0.84; P < 
0.01). In addition, there was a significant positive correla-
tion between MTTlymph and excess arm volume (r = 0.64; 
P = 0.04) and between MTTlymph and number of lymph 
nodes removed (r = 0.65; P = 0.03).There was no correla-
tion between MTTlymph and duration of lymphedema, hand 
involvement or dominance, age, BMI, or Szuba score. The 
Szuba score was significantly correlated exclusively with ex-
cess arm volume (Spearman’s rho, r = 0.64; P = 0.03; Fig. 2).
Interestingly, a positive correlation was found between 
number of lymph nodes removed and prior erysipelas (r = 
0.66; P = 0.03) as well as excess arm volume (r = 0.72; P = 
0.01), suggesting that the more lymph nodes removed, the 
greater the severity of lymphedema with a higher risk of 
later infection.
DISCUSSION
We used a newly developed lymphoscintigraphy-based 
quantitative measure, the MTT, to describe lymphatic 
function. In our small sample, MTT was strongly related 
to prior erysipelas infection and correlated with excess 
arm volume and number of axillary lymph nodes removed 
during breast cancer surgery, all of which are considered 
relevant markers of disease severity.3,15,16
Other studies have used simple ratios of ROIs between 
the healthy and lymphedema arm in the axillary regions, 
injection depots, or area of dermal backflow.5,6 The ap-
proach of using simple ratios between the 2 arms is depen-
dent on the contralateral side being healthy. In contrast, 
the MTT approach gives an independent value for each 
arm, which enables it to be used for unilateral as well as bi-
lateral lymphedema. Despite our effort to inject an equal 
amount of activity on both sides, we observed up to a fac-
tor of 3 in difference. A strength of our procedure is that 
this source of error is eliminated as we calculate the MTT 
Fig. 1.  a, representative scintigrams from both arms of a patient with the normal arm on top and the lymphedema arm on the bottom 
line. imaging was performed up to 5 hours after depot injection. On each image, the arm was marked (green), and a background correc-
tion in the surrounding arm was drawn (blue). the injection depot was marked (green circle), and a corresponding background correction 
was made (blue circle). the resulting graphs from the scintigraphy are depicted in B–e. On all graphs, blue is the normal arm and red is 
the lymphedema arm. B, time activity curve of injection depots. c, time activity curve of both arms. in all cases, the Mtt was longer in 
the lymphedema arm compared with the contralateral healthy arm. D, Modeled input function based on the minus derivative of the time 
activity curve of the injection depots. the y-axis is counts per minute entering the arm per minute. e, the retention function was modeled 
based on the measured time activity arm curve and the input function. the area under the retention function curve corresponds to the 
Mtt.
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solely based on the dynamics of the injection depot and 
the arm time activity curves; thus, the absolute amount of 
injected activity only has influence on the counts statis-
tics.13 An additional challenge with the axillary region is 
that it will have naturally reduced tracer accumulation fol-
lowing lymphadenectomy. This hampers the use of time 
to axillary lymph node visualization as a quantitative or 
semiquantitative measure.7
Removal rate from the injection depot has previously 
been proposed as an evaluation method. A study by Pain 
et al.17 showed that this rate was significantly different in 
affected and healthy arm. In contrast, we found no differ-
ence in removal rate between arms, which is in agreement 
with findings of Lane et al.9 who showed nearly identical 
removal rates from the injection depot in lymphedema 
patients and healthy control subjects, suggesting that this 
measure cannot stand alone as a measure of lymphatic 
dysfunction.
The MTT methodology distinguished itself by being 
able to discriminate between healthy and lymphedema 
Table 1.  Overview of the Characteristics of Included Patients
Patient No.
Age 
(y)
BMI (kg/ 
m2)
Excess Arm 
Volume 
(%)
Prior Skin 
Infection RT/CT
LNs with Mets/ 
No. Removed
LE Duration 
(mo)
MTTLE 
(min)
MTTHE 
(min) Szuba Score
01 56 32.7 7.9 No +/+ 1/25 15 24.7 7.44 5
02 45 41.8 11.6 No +/+ 1/19 35 27.1 4.7 7
03 52 23.6 5.8 No +/+ 4/11 27 49.9 5.8 3
04 68 22.3 12.4 No +/˗ 3/24 34 52.8 7.7 8
05 34 31.0 8.7 No +/+ 1/9 33 21.5 2.5 6
06 53 34.1 27.0 Yes +/+ 3/27 25 85.1 7.7 8
07 62 32.7 13.3 No +/+ 5/18 8 69.3 1.4 6
08 58 30.9 24.9 Yes ˗/+ 4/37 30 > 74.5 2.2 7
09 43 35.9 14.3 No +/+ 27/30 18 > 64.2 4.5 7
10 62 28.1 18.7 Yes +/+ 23/26 36 87.1 6.5 6
11 52 30.1 11.4 Yes +/+ 1/26 55 105.0 8.7 6
In 2 cases (patient 8 and 9), the 5-hour time range for imaging was not enough to identify the time point of decline in arm activity. The implication of this was that 
the MTT could not be accurately defined and only a minimum value was given.
CT, chemotherapy; HE, healthy; LE, lymphedema; LN, lymph node; Mets, metastases; RT, radiation therapy.
Fig. 2. correlation matrix. Overview of correlations visualized in a correlation matrix. P value was 
set at 0.05 and x marks all bivariate correlations that were not significant. Spearman rank cor-
relation was used in all analyses.
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arms with no overlap. A main strength of our proposed 
method is the use of the input and the retention function 
for calculation of the MTT through the arm. In theory, this 
makes the method independent of the injection method, 
whether intradermal, subdermal, or epifascial. Obviously, 
the same approach can also be applied for measuring low-
er extremity lymphedema.
Lymphatics are visualized faster with noncolloidal trac-
ers, including human serum albumin and by intradermal 
rather than subcutaneous injection.18–20 Despite the use 
of a fast tracer and intradermal injection technique, a 
decline in arm activity during our 5-hour scan time was 
not observed in 2 patients, meaning that sometimes the 
MTT cannot be calculated and only a minimum value can 
be obtained. In addition, in case of very limited tracer 
migration from injection depot, the MTT through the 
arm is determined with great uncertainty; however, this 
was not the case in any of the examined patients. Other 
limitations include the small number of patients in our 
sample, which increased the risk of overestimation bias. 
The reproducibility of the procedure is unknown due to 
lack of retesting and this will need to be confirmed be-
fore implementation. Results from a previous study re-
peating lymphoscintigraphy within a week concluded that 
lymphoscintigraphy is reproducible, at least with regard 
to the quantitative and qualitative markers used in that 
study.21 ROIs were manually drawn on each time frame, 
which may have introduced some error compared with an 
automated approach with reuse of the same ROIs, which, 
however, was not available to us.
In conclusion, preliminary clinical results with this 
novel quantitative lymphoscintigraphic approach seem 
to indicate that MTT measurements can reliably discrimi-
nate between presence and absence of lymphedema. If 
and when the reproducibility of the method has been 
confirmed, it may, thus, be suitable also for evaluation of 
therapeutic interventions. In addition, it may allow for 
comparison between institutions and is now open for fur-
ther validation in larger groups of patients being treated 
for breast cancer–related lymphedema.
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